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Abstract
Uncontrolled systemic activation of the immune system is an early initiating event that leads to development of acute
fulminant liver failure (FLF) in mice after treatment with agonistic Fas mAb. In this study, we demonstrate that treatment of
mice with N-acetylcysteine (NAC), an ROS scavenger and glutathione (GSH) precursor, almost completely abolished Fas
mAb-induced FLF through suppression of Va14iNKT cell activation, IFN-c signaling, apoptosis and nitrotyrosine formation in
liver. In addition, enrichment of the liver with GSH due to Va14iNKT cells deficiency, induced an anti-inflammatory response
in the liver of Ja18
2/2 mice that inhibited apoptosis, nitrotyrosine formation, IFN-c signaling and effector functions. In
summary, we propose a novel and previously unrecognized pro-inflammatory and pro-apoptotic role for endogenous ROS
in stimulating Th1 signaling in Va14iNKT cells to promote the development of FLF. Therefore, our study provides critical
new insights into how NAC, a ROS scavenger, regulates Th1 signaling in intrahepatic Va14iNKT cells to impact inflammatory
and pathological responses.
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Introduction
Fas (CD95), a 45-kDa type I membrane protein, is expressed on
numerous cell types including lymphoid cells (NK cells, T cells,
Va14iNKT cells) [1,2,3,4,5] and non-lymphoid cells such as
hepatocytes [1,2,3]. Fas, a member of the TNF receptor
superfamily, plays a vital role in regulating apoptosis in many
cell types and is typically stimulated by FasL or agonistic Fas mAb
[1,2]. Upon ligand binding, Fas-associated protein with death
domain and procaspase 8 are recruited to initiate caspase 8
proteolytic autocleavage, leading to activation of the effector
caspase, caspase 3, and ultimately cell death [1,2]. Fas activation is
often observed in diseases affecting many organ systems including
heart, lung and kidney. Of significant relevance, Fas activation is
a primary trigger for apoptotic death of hepatocytes [1,2]. The
fundamental concept that the liver is highly sensitive to Fas-
mediated apoptosis was first demonstrated in 1993 by Ogasawara
and colleagues [1] where systemic administration of agonistic Fas
mAb (Jo2) caused acute FLF, and ultimately mice mortality within
a few hours due to diffuse hemorrhage and massive apoptosis of
hepatocytes [1]. Although Fas activation is widely associated with
caspase-mediated cell death, growing evidence have increasingly
highlighted an important pro-inflammatory role for Fas in
promoting NF-kB/AP-1 activation [6,7,8], chemokine/cytokine
production [6,7,9] and leukocyte infiltration [6,7,9] in tissue sites.
Va14iNKT cells are thymic-derived innate T lymphocytes that
express a highly restricted TCR characterized by a Va14-Ja18
rearrangement [10]. Distinct from conventional T cells,
Va14iNKT cells respond to glycolipid antigens presented by
CD1d bearing antigen presenting cells [11]. Since the identity of
the endogenous glycolipid ligand that is responsible for
Va14iNKT cell selection and development in the thymus remains
elusive [12,13,14], characterization of several exogenous glycoli-
pids that Va14iNKT cells respond to, a-galactosylceramide
(GalCer) and its derivatives, has greatly facilitated the research
into the functional role of Va14iNKT cells in health and diseases
[13,14]. Notably, CD1d tetramers loaded with the prototypical
synthetic glycolipid antigen, a-GalCer, has been used to reveal
that murine liver has the highest frequency of resident Va14iNKT
cells [15,16]. Va14iNKT cells are activated in a TCR-dependent
manner by lipids presented by CD1d [17] or by TCR independent
mechanisms involving toll like receptors [17,18,19,20]. Following
activation, Va14iNKT cells may display cytotoxicity via Fas-FasL
and TRAIL-dependent death pathways [17], much like NK cells
[21]. However, their major function is thought to be rapid release
of copious amounts of immunopolarizing cytokines (including
IFN-c, IL-4 and TNF-a) and chemokines leading to stimulation or
suppression of immune responses [17]. Through these mediators,
activated Va14iNKT cells can ‘‘bridge’’ the innate and adaptive
immune systems by interacting with and transactivating immune
cells [22,23,24]. This ability to respond rapidly at the onset of the
immune response underscores the role of Va14iNKT cells in
immune response regulation. Consequently, Va14iNKT cells have
been demonstrated to play a critical role in several immune
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protection against various pathogens, including bacteria and
viruses [25,26].
We recently demonstrated that Ja18
2/2 mice, which are
specifically deficient in Va14iNKT cells, are highly resistant to
agonistic Fas mAb-induced acute FLF [5]. But the endogenous
mechanism(s) regulating the pathophysiological activities of
hepatic Va14iNKT cells are not known. In the present study,
we hypothesized that activation of the Fas receptor on liver
parenchymal cells, hepatocytes, by agonistic Fas mAb, initiates an
inflammatory response that induces an endogenous mediator,
possibly ROS, to regulate the pathophysiological effects of
intrahepatic Va14iNKT cell signaling during acute FLF.
Materials and Methods
Mice
Male C57BL/6 mice and IFN-c
2/2 mice (on C57BL/6
background) were purchased from the Jackson Laboratory (Bar
Harbor, ME). Breeding pairs of Ja18
2/2 mice (on C57BL/6
background) were kindly provided by Dr. M. Taniguchi (RIKEN
Research Center for Allergy & Immunology, Yokohoma, Japan)
[27] and bred in a pathogen-free breeding facility at LSUHSC-
Shreveport [5,20]. All mice were fed a standard chow pellet diet,
had free access to water and were maintained on a 12 h light/dark
cycle in a pathogen-free facility. All experiments were conducted
in accordance with National Institutes of Health and LSUHSC-
Shreveport guidelines for animal care. All experiments were
approved by LSUHSC-Shreveport Animal Care and User
Committee (Proposal #: P11-043).
Agonistic Fas (CD95) mAb-mediated FLF
Agonistic Fas mAb (clone Jo2; 0.5 mg/g of body weight; BD
Pharmingen; San Diego, CA) was administered intraperitoneally
to mice for 4.5 h to induce liver injury as we recently described
[5]. This dose of Fas mAb does not cause mice mortality. Control
mice received an equivalent volume of sterile PBS [28,29,30]. At
indicated time-point, mice were anesthetized with a mixture of
xylazine and ketamine hydrochloride and blood serum collected.
All livers were then perfused with ice-cold sterile PBS (to remove
blood elements) and harvested for experimental assays described
below. In some experiments, mice were treated with a single dose
of freshly prepared ROS scavenger, N-acetylcysteine (NAC;
300 mg/kg, i.p.; Sigma) [20,31] immediately after Fas mAb
treatment.
Glutathione (GSH) Measurement
Perfused livers were snap-frozen in liquid nitrogen immediately
after excision from mice. Total GSH in liver was determined in
trichloroacetic acid supernatants by high-performance liquid
chromatography (HPLC) using a modified protocol of Reed et al.
[32] as we previously described [33,34]. Briefly, experimental
samples were derivatized with 6 mM iodoacetic acid and 1%
2,4-dinitrofluorobenzene to yield the S-carboxymethyl and 2,4-
dinitrophenyl derivatives, respectively. Separation of GSH de-
rivative was performed on a 25064.6-mm Alltech Lichrosorb
NH2 10-mm column using a Shimadzu HPLC system. Proteins in
the acid pellet were solubilized in 0.1 M NaOH, and protein was
determined using the Bio-Rad Protein Assay kit (Bio-Rad,
Hercules, CA). GSH concentration was determined by compar-
ison with purified GSH standards derivatized in the same
manner.
Western Blot Analysis
Perfused mice livers were homogenized in RIPA buffer (50 mM
Tris-HCl pH 7.4, 1% Nonidet-P40, 0.25% Sodium deoxycholate,
150 mM NaCl, 1 mM EDTA, 1 mM Dithiothreitol and protease
inhibitors). Equal volumes of 2x sample buffer were added to liver
protein extract. Next, liver protein samples (50 mg/lane) were
fractionated by SDS-PAGE and then transfered onto PVDF
membrane (Thermo Scientific; Rockford, IL). After which,
membranes were blocked with 5% fat-free milk for 1 h at room
temperature followed by overnight incubation with the following
primary antibodies at depicted dilutions/concentrations: active
caspase 3 (1:1000); pSTAT-1 (1:500); T-bet (1:1000), GAPDH
(1:1000) and Nitrotyrosine (1:1000). Membranes were then
counterstained with corresponding horseradish peroxidase-conju-
gated secondary antibodies for visualization by Pierce ECL
western blotting reagent (Thermo Scientific). Each membrane
was stripped in buffer (0.5 mM Tris-HCl pH 6.8, 10% SDS,
0.08% Mercaptoethanol) and probed for GAPDH to verify equal
protein loading in samples. Active caspase 3 Ab (clone 269518)
was obtained from R & D systems (Minneapolis, MN) whereas
pSTAT-1 (Tyr701) Ab was supplied by BD Pharmingen.
Antibodies for T-bet (4B10) and GAPDH were all purchased
from Santa-Cruz Biotech (Santa-Cruz, CA) and Nitrotyrosine
mAb (clone HM11) was supplied by Invitrogen (Camarillo, CA).
Biochemical and Histological Liver Injury
Acute liver injury was evaluated by biochemical and histological
means. Biochemical assessment of liver damage was determined
by serum levels of the liver enzyme, alanine aminotransferase
(ALT) using a commercial kit (Thermo Electron, Waltham) [5,35].
For histological evaluation, paraffin embedded liver sections (5 mm
thick) were deparaffinized, stained with H & E according to
standard protocols and then analyzed by light microscopy in
a blinded fashion by a pathologist (PAA). The degree of
inflammation in the liver and hepatocyte damage was graded as
none (0), mild (,25%), moderate (25%–50%) and severe (.50%)
using a combination of indices: severity of the inflammation and
degree of hepatocyte degenerative changes including hepatocyte
necrosis, hemorrhage and frequency of acidophilic bodies [5,35].
In Situ Analysis of Liver Apoptosis Using TUNEL
Paraffin-embedded liver sections were dewaxed in xylene and
rehydrated by passage through a graded series of ethanol solutions,
and then PBS. Sections were permeabilized with proteinase K
(20 mg/ml in 10 mM Tris-HCl, pH 7.4–8.0) at 37uC for 15 min,
washed and then stained with fluorescein nucleotide mixture with
terminal deoxynucleotidyl transferase (TdT) from In Situ Cell
Death Detection kit (Roche Applied Science; Indianapolis, IN).
Sections were viewed and photographed using standard fluores-
cent microscopic techniques.
Hepatic Lymphocytes Isolation and Flow Cytometry
Hepatic lymphocytes were isolated using our published proto-
cols [16,20,35]. To specifically identify Va14iNKT cells by flow
cytometry, isolated hepatic lymphocytes were preincubated with
anti-mouse CD16/32 mAb (clone 2.4G2; BD Pharmingen) to
block FccRs and then incubated simultaneously with fluoro-
chrome-labeled TCRb mAb (clone H57-597; eBiosciences, San
Diego, CA) and fluorochrome-labeled Va14iNKT cell tetramer
(CD1d-PBS57; NIH Tetramer Core Facility, Atlanta) [5,20,35].
CD25 expression on the surface of tetramer positive hepatic
Va14iNKT cells was determined by FACS after staining with
fluorochrome-labeled murine CD25 mAb (clone PC61.5; eBios-
NAC Inhibits Va14iNKT Cell Activation
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38051NAC Inhibits Va14iNKT Cell Activation
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38051ciences). For measurement of intracellular IFN-c, TNF-a and
active caspase 3, tetramer positive Va14iNKT cells were first
permeabilized using the Cytoperm/fix kit (BD Pharmingen) and
then stained with either fluorochrome-labeled murine IFN-c mAb
(clone XMG1.2; BD Pharmingen) [5,35], fluorochrome-labeled
murine TNF-a mAb (clone MP6-XT22; eBioscience) [20] or
fluorochrome-labeled active caspase 3 mAb (clone C92-605; BD
Pharmingen) [5,16,20]. In all experiments, cells were analyzed
directly ex vivo without cell culture treatment with brefeldin A or
monensin. Corresponding isotype antibody/tetramer was used to
set analysis gates. In addition, viable lymphocyte populations were
gated using forward and side scatter characteristics and data
analyzed using the FACS Calibur and FACS Scan Diva software
(BD Pharmingen).
Statistical Analysis
All data are shown as mean 6 SEM. For comparisons of means
between 2 experimental groups, a Student unpaired t test was
used. Comparison among three or more experimental groups was
performed using a one-way ANOVA, followed by Newman-Kuels
post hoc test. A value of p,0.05 was considered significant.
Results
Resistance of Va14iNKT Cells Deficient Mice to FLF is
Associated with Decreased Th1 Differentiating Signaling
in Liver
We first confirmed our recent observation [5] that the presence
of hepatic Va14iNKT cells promote acute FLF in response to
agonistic Fas mAb treatment. Specifically, we found that Fas mAb
administration into WT mice caused a significant increase in
serum ALT level whereas Ja18
2/2 mice were highly resistant to
acute FLF as reflected by almost complete suppression (.90%
reduction) of serum ALT (Figure 1A). In parallel, liver sections
from WT mice exhibited extensive hepatocyte apoptosis and
necrotic damage following Fas mAb treatment relative to livers
from Ja18
2/2 mice which displayed mild hepatocyte damage
(Figure 1C and D). Specifically, the degree of hepatic inflamma-
tion and hepatocyte damage in WT mice after Fas mAb treatment
was graded as severe (.50%) relative to mild (,25%) in Ja18
2/2
mice. As expected, normal serum ALT levels was observed in both
naive WT and J Ja18
2/2 mice (Figure 1A). In the present study,
we provide new data demonstrating that resistance of Ja18
2/2
mice to FLF was associated with a dramatic decrease in hepatic
apoptosis as revealed by reduced expression of active caspase 3
and TUNEL staining in the liver (Figure 1E and 1F). The finding
that active caspase 3 expression was not completely suppressed in
Ja18
2/2 mice after Fas mAb treatment suggests that other hepatic
cells apart from intrahepatic Va14iNKT cells may also contribute
to apoptosis. It is notable that reduced susceptibility of Ja18
2/2
mice to FLF was also accompanied by striking reductions in
hepatic expression of Th1 differentiating signaling molecules,
pSTAT-1 and T-bet (Figure 1E). To determine whether oxidative
and nitrosative stress may also contribute to the development of
FLF, we measured nitrotyrosine formation (a product of
nitrosative stress) and the ROS scavenger, GSH. We observed
a striking increase in nitrotyrosine formation in the liver of WT
mice but not Ja18
2/2 mice after Fas mAb administration
(Figure 1E). Remarkably, we also found that Fas mAb-mediated
FLF in WT mice caused a significant decrease in hepatic GSH
(relative to PBS-treated WT mice), but GSH levels were restored
in the absence of Va14iNKT cells (i.e. in Ja18
2/2 mice) during
mild FLF to levels seen in PBS-treated WT mice (Figure 1G).
Agonistic Fas mAb Promotes Intrahepatic Va14iNKT Cell
Activation
We next verified by flow cytometry that hepatic Va14iNKT
cells were activated following agonistic Fas mAb administration in
WT mice as denoted by upregulation of the activation marker,
CD25, on cell surface (Figure 2A and B) and by increased
intracellular IFN-c expression by hepatic Va14iNKT cells
(Figure 2C and D). In addition, we established that the ROS
scavenger, NAC, effectively suppressed hepatic Va14iNKT cells
CD25 and IFN-c expression in WT mice during Fas mAb-
mediated FLF (Figure 2A, B, C, D). Although CD25 expression by
hepatic Va14iNKT cells in NAC-treated WT mice during Fas
mAb-mediated FLF was 2-fold higher than PBS control, it was not
significant (Figure 2B). In contrast, hepatic Va14iNKT cells IFN-c
expression in NAC-treated WT mice during Fas mAb-mediated
FLF was significantly higher (i.e. 3-fold) than PBS control
(Figure 2C). Moreover, the number of CD25-positive cells but
not IFN-c positive cells in the liver of WT mice after NAC/Fas
mAb treatment was significantly higher than PBS control (Figure
S1). It is noteworthy that Va14iNKT cells from the liver of Fas
mAb-treated WT mice lack intracellular TNF-a (Figure 2E) and
active caspase 3 (Figure 2F).
Pathophysiological Role of IFN-c During Fas mAb-
dependent FLF
In view of our preceding findings, we next treated WT and
IFN-c
2/2 mice with agonistic Fas mAb to evaluate whether
IFN-c is an essential and direct participant in FLF. As shown in
Figure 3A, both WT and IFN-c
2/2 mice were similarly
susceptible to acute FLF since serum ALT levels in both mice
strains were comparable. In correlation, histological evaluation of
liver sections showed that the degree of hepatic inflammation
and hepatocyte damage in both strains of mice was severe
(.50%; Figure 3B, top panels). Histological scoring criteria was
based on the severity/magnitude of inflammation, and the
degree of hepatocyte degenerative changes including hepatocyte
necrosis, hemorrhage and frequency of acidophilic bodies [5,35].
Likewise, active caspase 3 expression and tunnel staining in the
liver during IFN-c deficiency was comparable to levels in WT
mice during Fas mAb-mediated acute FLF (Figure 3C and D). It
Figure 1. Th1 differentiating signaling in the liver is dysregulated by Va14iNKT cells deficiency during Fas mAb-induced FLF. (a)
Serum ALT levels of naı ¨ve WT mice, Fas mAb-treated WT and Ja18
2/2 mice at 4.5 h. (b–d) H & E staining of liver sections from naı ¨ve WT mice, Fas
mAb-treated WT and Ja18
2/2 mice at 4.5 h. Livers from Fas mAb-treated WT mice (c) showed extensive damage with destruction of hepatocytes and
distortion of normal liver architecture. The hepatocytes show hemorrhagic necrosis (white arrows) and characteristic signs of apoptosis (black arrows)
including chromatin condensation and cellular shrinkage. In comparison, livers from Fas mAb-treated Ja18
2/2 mice showed only minimal damage
and retained the normal architecture (d). Liver from a naı ¨ve WT mouse is illustrated in (b) for comparison. (e) Western blot analysis of active caspase
3, T-bet, pSTAT-1, nitrotyrosine and GAPDH expression in the liver of PBS-treated WT mice and agonistic Fas mAb-treated WT and Ja18
2/2 mice at
4.5 h. (f) TUNEL staining of liver sections from WT and Ja18
2/2 mice at 4.5 h after Fas mAb injection in which WT mice showed intense TUNEL
staining characteristic of apoptosis whereas Ja18
2/2 mice showed less/reduced TUNEL staining. (g) HPLC measurement of hepatic GSH levels in PBS-
treated WT mice and Fas mAb-treated WT and Ja18
2/2 mice at 4.5 h. Figure S1 in a and g are presented as mean 6 s.e.m with n=5 mice/group;
*P,0.05 by one-way analysis of variance followed by Newman-Kuels post hoc test. All experiments were conducted twice.
doi:10.1371/journal.pone.0038051.g001
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FACS histograms of extracellular CD25 (a), intracellular IFN-c (d), intracellular TNF-a (e; aGalcer used as a positive control) and intracellular active
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T-bet in the liver of WT mice during FLF was not suppressed by
IFN-c deficiency (Figure 3C). Likewise, nitrotyrosine formation
in the liver of WT mice was comparable to IFN-c
2/2 mice
during Fas mAb-mediated acute FLF (Figure 3E). These data
strongly suggests that IFN-c may not be a key and/or direct
mediator of FLF in response to agonistic Fas mAb treatment.
NAC Therapy Alleviates Fas mAb-dependent FLF During
IFN-c Deficiency
We demonstrated in Figure 1G that resistance of Ja18
2/2 mice
to hepatic failure may be associated with elevated GSH levels.
GSH has been reported to ameliorate Fas mAb-dependent FLF
[30,36]. For this reason, we evaluated the effects of NAC, a GSH
precursor and ROS scavenger, on the development of FLF in WT
and IFN-c
2/2 mice in response to agonistic Fas mAb. Impor-
tantly, we observed that WT mice were strikingly resistant to Fas
mAb-dependent FLF following NAC treatment as denoted by
considerably lower ALT levels relative to Fas mAb-treated WT
mice given PBS (Figure 3A). Equally significant, FLF in IFN-c
2/2
mice was almost completely resolved by NAC therapy relative to
Fas mAb-treated IFN-c
2/2 mice administered PBS (Figure 3A).
In parallel, histological injury in both strains of mice was found to
be minimal (Figure 3B) after NAC therapy since the scale of
hepatic inflammation and hepatocyte damage in both strains of
mice were graded as very mild to none. Notably, NAC therapy in
WT and IFN-c
2/2 mice also markedly suppressed hepatic
apoptosis as revealed by active caspase 3 (Figure 3C) and TUNEL
staining (Figure 3D). Additionally, pSTAT-1 (Figure 3C), T-bet
(Figure 3C) expression and nitrotyrosine formation (Figure 3E) in
the liver of WT and IFN-c
2/2 mice were all suppressed by NAC
therapy. These findings suggest a fundamental role for endogenous
ROS in regulating Th1 differentiating signaling and nitrosative
stress in the liver during Fas mAb-dependent FLF.
NAC Therapy Prevents Hepatic Va14iNKT Cell
Accumulation During FLF
Given the anti-inflammatory effects of NAC therapy on Fas
mAb-dependent FLF and Th1 differentiating signaling, we next
determined whether NAC may also inhibit intrahepatic
Va14iNKT cell accumulation. Indeed, we found that NAC
therapy effectively diminished the frequency of Va14iNKT cells in
the liver of WT mice undergoing acute FLF (Figure 4A and B). It
is also notable that the frequency of Va14iNKT cells in the liver of
WT mice treated only with NAC (i.e. in the absence of agonistic
Fas mAb) did not significantly differ from WT mice given only
PBS (Figure 4C), suggesting that endogenous ROS produced in
inflamed liver during agonistic Fas mAb-mediated FLF may be
driving the effects seen on intrahepatic Va14iNKT cell accumu-
lation.
Effects of NAC Therapy on Va14iNKT TCR
Downregulation
These experiments were designed to determine whether the
suppressive effects of NAC therapy on Va14iNKT cells accumu-
lation in the liver during agonistic Fas mAb-mediated FLF could
be due to down-modulation of surface TCR. Our results showed
that surface TCRb on Va14iNKT cells was not downregulated by
NAC therapy during Fas mAb-induced FLF since the geometric
mean fluorescence intensity (MFI) of surface TCRb after NAC
treatment was comparable to WT mice administered PBS (MFI:
15486354 in WT/NAC/Fas mAb relative to 15396343 in WT/
PBS/Fas mAb; n=6 mice/group).
Discussion
Engagement of the Fas receptor typically leads to apoptosis
[1,2,3]. The importance of the Fas/FasL system in hepatic
apoptosis has been convincingly demonstrated in both experi-
mental and clinical liver injury models including viral and
autoimmune hepatitis, alcoholic liver disease and acute liver
failure [1,2,3,5,37,38]. Therefore, strategies for downregulating
the Fas/FasL system might have therapeutic value in the
treatment of these human diseases. In addition to its role in
caspase-mediated cell death, emerging studies have increasingly
proposed an inflammatory role for agonistic Fas mAb in
stimulating intracellular signaling pathways in target cells, such
as hepatocytes, astrocytes and epithelial cells, leading to NF-kB
and/or AP-1 activation [6,7,8], chemokine/cytokine production
[6,7] and leukocyte infiltration [6,7,9] in tissue sites. Va14iNKT
cells represent a critical link between the innate and adaptive
immune systems and play an important immunoregulatory role in
hepatic, cardiovascular, infectious and autoimmune diseases as
well as in tumor immunity. We recently demonstrated that mice
deficient in Va14iNKT cells (i.e. Ja18
2/2 mice) are highly
resistant to acute FLF in response to Fas mAb treatment [5]. But,
there are notable deficiencies in our knowledge regarding whether;
(i) agonistic Fas mAb directly stimulates intrahepatic Va14iNKT
cells to induce effector functions or (ii) inflammatory mediator(s)
are produced in the liver in response to agonistic Fas mAb
treatment to alter/regulate the biological/functional effects of
intrahepatic Va14iNKT cells. The current study highlights a novel
dual pro-inflammatory and pro-apoptotic role for endogenous
ROS in mediating agonistic Fas mAb-dependent acute FLF by
promoting intrahepatic Va14iNKT cell activation and effector
functions.
During inflammatory responses, Va14iNKT cells are rapidly
activated by TCR-dependent and independent mechanisms
[17,18,19,20] to produce significant amounts of immunopolariz-
ing cytokines including the Th1 cytokine, IFN-c [16] and TNF-
a [20]. For this reason, we initially ascertained the activation
status of intrahepatic Va14iNKT cells in response to agonistic
Fas mAb treatment. We observed by FACS analysis that hepatic
Va14iNKT cells are activated to upregulate extracellular CD25
and intracellular IFN-c expression but not TNF-a. Our
approach of using intracellular IFN-c production and/or
extracellular CD25 expression to denote Va14iNKT cell
activation is widely supported by multiple studies from our
laboratory [5,20] and others [22,39,40,41,42,43,44,45]. Since
many of the effects of IFN-c are STAT-1 and T-bet dependent
[46,47,48], we also determined by western blotting if these Th1
differentiating signaling molecules are differentially regulated in
the presence and absence of Va14iNKT cells following Fas mAb
administration. Consistent with this notion, we found that
pSTAT-1 and T-bet levels in the liver were markedly diminished
in the absence of Va14iNKT cells. Additionally, markers of
apoptosis (i.e. active caspase 3 and TUNEL staining) and
caspase 3 (f; Adenovirus used as a positive control) expression levels by intrahepatic Va14iNKT cells at 4.5 h after PBS or agonistic Fas mAb treatment.
All experiments were performed twice. Figure S1 in b and c are presented as mean 6 s.e.m with n=4 mice/group; *P,0.05 by one-way analysis of
variance followed by Newman-Kuels post hoc test.
doi:10.1371/journal.pone.0038051.g002
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38051Figure 3. NAC therapy ameliorates agonistic Fas mAb-induced FLF during IFN-c deficiency. (a) Serum ALT levels in WT and IFN-c
2/2 mice
after PBS or NAC treatment during agonistic Fas mAb-induced FLF. (b) H & E staining of liver sections of WT and IFN-c
2/2 mice after PBS or NAC
treatment during agonistic Fas mAb-induced FLF. As shown in top panel, livers from Fas mAb-treated WT and IFN-c
2/2 mice displayed widespread
hepatocyte damage including hemorrhagic necrosis (white arrows) and apoptosis (black arrows) that distorted normal liver architecture. In contrast,
liver sections of WT and IFN-c
2/2 mice treated with NAC during Fas mAb-induced FLF (bottom panel) showed reduced hepatocyte damage and
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the deficiency in Va14iNKT cells during Fas mAb-dependent
FLF. Therefore, we propose that Va14iNKT cells positively
regulates the expression of Th1 differentiating signaling media-
tors, IFN-c, STAT-1 and T-bet, in the liver as well as liver
apoptosis and nitrosative stress during Fas mAb-dependent FLF.
To provide proof-of-principle that the pro-inflammatory/
pathological effects of intrahepatic Va14iNKT cells could be
directly mediated by IFN-c, we examined the effects of IFN-c
deficiency on the development of Fas mAb-dependent FLF.
Astonishingly, IFN-c mutant mice were similarly susceptible to Fas
mAb-induced FLF as WT mice. In correlation, a previous study
demonstrates that IFN-c can exert liver inflammation/injury
independent of Fas [49]. Furthermore, hepatic apoptosis was not
alleviated by IFN-c deficiency since expression of active caspase 3
and TUNEL positive cells in the liver of IFN-c mutant mice was
comparable to WT mice. Although STAT-1 and T-bet are usually
critical to IFN-c signaling, we found that IFN-c is dispensable for
hepatic induction of pSTAT-1 and T-bet following Fas mAb
treatment since their expression was not inhibited by IFN-c
deficiency. In view of the fact that pSTAT-1 is an upstream
transcription factor known to induce caspase 3-dependent
apoptosis [46,47] and T-bet activation [46,48], we speculated
that endogenous factor(s) upstream of IFN-c may be early
activator(s) of STAT-1 and T-bet. With this in mind, our
subsequent experiments were designed to establish if treating
mice with NAC to block ROS, an endogenous mediator produced
in the liver (i.e. hepatocytes) during Fas mAb-induced FLF
[50,51,52], may suppress IFN-c signaling. Alternatively, NAC
may directly inhibit pSTAT-1 and T-bet activation independent of
IFN-c.
retained near normal architecture. (c&e ) Western blot analysis of hepatic active caspase 3, T-bet, pSTAT-1 expression levels and nitrotyrosine
formation in WT and IFN-c
2/2 mice after PBS or NAC treatment during Fas mAb-induced FLF. (d) TUNEL staining of liver sections from WT and IFN-
c
2/2 mice treated with PBS during Fas mAb-induced FLF showed intense TUNEL staining characteristic of apoptosis whereas WT and IFN-c
2/2 mice
treated with NAC mice showed minimal TUNEL staining. Figure S1 in a are presented as mean 6 s.e.m with n=3–6 mice/group. *P,0.05,
?P,0.05 by
one-way analysis of variance followed by Newman-Kuels post hoc test. All experiments were performed twice.
doi:10.1371/journal.pone.0038051.g003
Figure 4. Effect of NAC treatment on intrahepatic Va14iNKT cell accumulation during Fas mAb-induced FLF. (a) Representative FACS
dot plot of Va14iNKT cells levels in the liver after PBS or NAC treatment during Fas mAb-induced FLF. (b) FACS analysis of Va14iNKT cells level in the
liver after PBS or NAC treatment in response to Fas mAb-induced FLF. (c) FACS analysis of Va14iNKT cells level in the liver after PBS or NAC treatment
only (i.e. in the absence of agonistic Fas mAb). Results in b and c are shown as mean 6 s.e.m with n=4–6 mice/group with *P,0.05 by Student’s
unpaired t test. All experiments were conducted twice. Broken lines denote levels in untreated mice.
doi:10.1371/journal.pone.0038051.g004
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a result of complex pathophysiological events involving injurious
factors such as ROS. For example, studies highlighting the
deleterious consequences of GSH depletion in Fas mAb-mediated
FLF underscore the importance of this anti-oxidant [30,36].
Likewise, administration of MnTBAP (a nonpeptidyl mimic of
superoxide dismutase) [51] prevents Fas mAb-induced FLF.
Further, GSH enrichment alleviates Fas mAb-induced acute
FLF [30]. For this reason, we next determined the effect of NAC
treatment on IFN-c signaling during Fas mAb-induced FLF by
treating IFN-c
2/2 mice with NAC. We demonstrate for the first
time that NAC therapy diminished hepatic injury in IFN-c
2/2
mice during Fas mAb-dependent FLF probably via suppression of
hepatic Th1 signaling molecules (i.e. pSTAT-1 and T-bet),
apoptosis and nitrotyrosine formation. However, our observation
that pSTAT-1 and T-bet expression in both vehicle and NAC
treatment groups in IFN-c
2/2 mice was higher than in WT mice
suggests a possible inhibitory role of IFN-c
2 that may not involve
caspase 3. This observation warrants further investigation. Taken
together, these studies provide important evidence that NAC
therapy regulates IFN-c signaling and effector functions during
Fas mAb-induced FLF. An important question our study also
addressed is why Ja18
2/2 mice are resistant to development of
FLF and hepatic apoptosis following Fas mAb administration. It is
notable that Fas stimulation induces hepatic GSH depletion by
triggering a cellular efflux of reduced GSH [53,54]. Conversely,
preventing Fas induced GSH depletion attenuates apoptosis [30].
In agreement, we observed that GSH levels in the liver of WT
mice was significantly depleted in response to agonistic Fas mAb
treatment, but completely restored by V Va14iNKT cell de-
ficiency to levels seen in PBS-treated WT mice. As mentioned
previously, hepatic apoptosis (as denoted by active caspase 3 and
TUNEL staining), pSTAT-1 and T-bet levels in the liver were
markedly diminished by Va14iNKT cell deficiency during Fas
mAb-induced FLF. On the basis of these findings, we surmised
that fortification of hepatic GSH due to absence of Va14iNKT
cells generates anti-inflammatory responses that suppresses IFN-c
signaling and effector functions in the liver to prevent/limit the
development of FLF and hepatic apoptosis in Ja18
2/2 mice.
We previously discussed that intrahepatic Va14iNKT cells are
activated during agonistic Fas mAb-induced FLF to express
extracellular CD25 and intracellular IFN-c. However, it is not
Figure 5. A proposed model depicting the sequential molecular and cellular events of NAC therapy regulation of Va14iNKT cells
signaling in the liver during Fas mAb-induced FLF. An endogenous mediator inhibited by NAC (possibly ROS) mediates Fas mAb-dependent
FLF by promoting intrahepatic Va14iNKT cells signaling, upregulation of pSTAT-1 and pSTAT-1-regulated genes, caspase 3 and T-bet, induction of
hepatocyte damage and fatal/lethal immunopathological events in the liver that ultimately leads to FLF.
doi:10.1371/journal.pone.0038051.g005
NAC Inhibits Va14iNKT Cell Activation
PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e38051known whether agonistic Fas mAb is capable of directly
stimulating intrahepatic Va14iNKT cells. Work by us [5,16]
and others [4,40,55] in several animal models have previously
demonstrated that intrahepatic Va14iNKT cell activation during
inflammatory responses is associated with a significant decline in
the frequency of hepatic Va14iNKT cells due to death by
apoptosis, a process known as activation-induced cell death
(AICD). In the present study, we provide evidence supporting
the notion that agonistic Fas mAb is unlikely to directly stimulate
intrahepatic Va14iNKT cells to undergo AICD. Specifically, Fas
mAb treatment in WT mice did not cause a decline in intrahepatic
Va14iNKT cells since the frequency of intrahepatic Va14iNKT
cells in Fas mAb-treated WT mice was comparable to PBS-treated
WT mice. Furthermore, intrahepatic Va14iNKT cells lack
intracellular active caspase 3 upon Fas mAb treatment. Hence,
we next assessed the effect of NAC therapy on intrahepatic
Va14iNKT cell activation during Fas mAb-induced FLF.
Recently, we showed that NAC therapy inhibits intrahepatic
Va14iNKT cell activation during poly I:C-induced liver in-
flammation [20]. To further explore the effect of NAC therapy on
intrahepatic Va14iNKT cell activation in this study, Va14iNKT
cells extracellular CD25 and intracellular IFN-c expression were
determined. Significantly, we found that NAC therapy effectively
curbed intrahepatic Va14iNKT cell activation (i.e. extracellular
CD25 and intracellular IFN-c expression) in WT mice during Fas
mAb-induced FLF. Equally important, liver pathology, hepatic
apoptosis and IFN-c signaling in WT mice were all diminished by
NAC treatment during FLF. It is also notable that the frequency of
Va14iNKT cells in the liver of WT mice undergoing Fas mAb-
induced FLF was also significantly decreased by NAC therapy. In
contrast, NAC only treatment of WT mice (i.e. in the absence of
agonistic Fas mAb) did not alter the frequency of Va14iNKT cells
in the liver relative to WT mice treated only with vehicle (i.e. in the
absence of agonistic Fas mAb). These results indicate that NAC
effectively suppresses the endogenous mediator produced by
inflamed liver to drive the effects seen in intrahepatic Va14iNKT
cells during agonistic Fas mAb-mediated FLF. It is generally
accepted that the decline/disappearance of Va14iNKT cells
during inflammatory responses may result from TCR down-
regulation and/or apoptosis [4,5,16,39,55,56,57]. In the current
study, we observed that surface TCR on Va14iNKT cells was not
down-regulated by NAC therapy during Fas mAb-induced FLF.
Furthermore, NAC therapy did not promote apoptosis of
intrahepatic Va14iNKT cells following agonistic Fas mAb
administration. Although beyond the scope of the current study,
it is conceivable that NAC therapy may suppress the production of
chemoattractant(s) critical to Va14iNKT cells accumulation in the
liver during FLF. This is an area that warrants further in-
vestigation.
In summary, the current study reveals new insights into how
NAC therapy regulates IFN-c signaling in Va14iNKT cells to
impact inflammatory and pathological responses in the liver
(Figure 5) and possibly other tissue sites (such as heart, lung and
kidney) where Fas activation is often observed.
Supporting Information
Figure S1 Effect of NAC treatment on intrahepatic
Va14iNKT cell CD25 expression during agonistic Fas
mAb-induced FLF. The number of CD25-expressing
Va14iNKT cells in the liver after PBS or NAC treatment during
Fas mAb-induced FLF at 4.5 h. All experiments were performed
twice. Data is presented as mean 6 s.e.m with n=4 mice/group
(Figure S1); *P,0.05 vs. PBS group (no Fas mAb treatment);
*P,0.05 vs. NAC/Fas mAb-treated group. #P,0.05 vs PBS
group (no Fas mAb treatment); #P,0.05 vs. PBS/Fas mAb-
treated group. Analysis performed by one-way analysis of variance
followed by Newman-Kuels post hoc test.
(TIF)
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